[Present status and problems in biologics for treatment of rheumatoid arthritis in Japan].
Takeuchi
Tsutomu
T
D000068879:Adalimumab; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D001688:Biological Products / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D004359:Drug Therapy, Combination; D000068800:Etanercept; D019317:Evidence-Based Medicine; D007074:Immunoglobulin G; D000069285:Infliximab; D015850:Interleukin-6; D007564:Japan; D008727:Methotrexate; D017410:Practice Guidelines as Topic; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D007074:Immunoglobulin G; D015850:Interleukin-6; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; C502936:tocilizumab; D000068800:Etanercept; D008727:Methotrexate